Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Trial Profile

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; Botensilimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Panitumumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BBOpCo

Most Recent Events

  • 23 Feb 2025 According to an Agenus Inc media release, a Trial-in-Progress (TiP) poster data will be presented from this study at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California.
  • 20 Nov 2024 Status changed from not yet recruiting to recruiting.
  • 19 Sep 2024 Planned initiation date changed from 1 Jul 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top